HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Allergy & Immunology
Meta-analysis
Switching Biologics in Severe Asthma Patients Shows Improved Clinical Outcomes and Reduced Exacerbations Across Multiple Therapies
Switching Asthma Drugs Could Change Your Life
A systematic review and meta-analysis of 2,292 patients found that switching biologics significantly reduced exacerbations and improved asth…
If your severe asthma medication stops working, switching to a different biologic drug could cut your attacks in half and help you breathe e…
May 5, 2026
Drug Pipeline
Sys. Review
Narrative review discusses tezepelumab for severe asthma in type 2-low patients on GINA Step 4–5 therapy
New Asthma Drug Works for Hard-to-Treat Patients Who Had Few Options
This narrative review examines tezepelumab for severe asthma, specifically focusing on type 2-low patients currently prescribed GINA Step 4–…
This new treatment offers hope for severe asthma patients who don’t respond to standard therapies, including a group previously left out of …
Frontiers
Apr 24, 2026
Allergy & Immunology
Cohort
Baseline inflammation patterns in severe asthma patients receiving biologic therapy
Severe asthma patients with neutrophilic patterns had lower lung function and more sleep apnea
This retrospective observational cohort study analyzed 103 patients with severe asthma treated with biologic agents.
Severe asthma patients with neutrophilic patterns had lower lung function and more sleep apnea than those with other inflammation types.
Frontiers
Apr 9, 2026
Allergy & Immunology
Sys. Review
Asia-Pacific experts propose clinical remission definition and lung function goals for severe asthma
What does it mean to beat severe asthma in Asia? Experts propose new goals
A position statement by Asia-Pacific experts reviewed severe asthma management challenges in the region.
Experts redefine severe asthma success in Asia by prioritizing symptom control and stability over impossible lung function recovery.
Frontiers
Apr 1, 2026
Allergy & Immunology
Phase II
VALIANT: Phase 2 trial of verekitug (UPB-101) for severe asthma completes enrollment of 479 patients
Can a new injection help people with severe asthma breathe easier and avoid dangerous flare-ups?
The VALIANT study, a phase 2 trial, evaluated the efficacy and safety of subcutaneous verekitug (UPB-101) versus placebo in adults with seve…
A new asthma injection aims to reduce dangerous flare-ups and improve breathing for adults with severe asthma in a completed trial.
CT.gov
Mar 30, 2026